stockrowAxoGen, Inc.
AXGN Healthcare Medical Devices
AxoGen, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $225.2 million, up 20.2% from fiscal 2024.
- Revenue
- +26.2%
- EPS
- +163.2%
- Free cash flow
- +995.0%
- Total debt
- −73.1%
Quarter to September 2026, against a year earlier
Follow AXGN
Alert me
AxoGen, Inc. (AXGN) Current ratio
AxoGen, Inc.'s current ratio at the end of the quarter to 30 September 2026 was 12.0×, up 6.9× from fiscal 2025 (5.1×). Over the past ten years it has ranged from 2.9× (fiscal 2023) to 11.6× (fiscal 2018); the current reading is higher than 55% of that period. That is above the Medical Devices industry median of 2.7× and above the Healthcare sector median of 3.1×.
Current ratio, annual
Embed this chart
Annual newest first
| Period | Current ratio | Change |
|---|---|---|
| FY2025 | 5.1× | 57.72% |
| FY2024 | 3.2× | 12.08% |
| FY2023 | 2.9× | (29.96%) |
| FY2022 | 4.1× | (21.05%) |
| FY2021 | 5.2× | (17.79%) |
| FY2020 | 6.4× | (1.62%) |
| FY2019 | 6.5× | (44.12%) |
| FY2018 | 11.6× | 184.82% |
| FY2017 | 4.1× | 2.24% |
| FY2016 | 4.0× | (57.95%) |
Quarterly newest first
| Period | Current ratio | Change |
|---|---|---|
| Sep 2026 | 12.0× | 82.16% |
| Jun 2026 | 6.6× | (7.09%) |
| Mar 2026 | 7.1× | 38.90% |
| Dec 2025 | 5.1× | 25.10% |
| 43 more quarters | Free account |
Against its own ten years
Current ratio against peers
| Company | Current ratio |
|---|---|
| AXGN AxoGen, Inc. | 12.0× |
| ALMR Alamar Biosciences, Inc. compare | 9.5× |
| INSP Inspire Medical Systems, Inc. compare | 6.4× |
| TMDX TransMedics Group, Inc. compare | 4.5× |
| ITGR Integer Holdings Corporation compare | 4.0× |
| NEOG Neogen Corporation compare | 3.9× |
| ESTA Establishment Labs Holdings Inc. compare | 3.8× |
| IRTC iRhythm Holdings, Inc. compare | 3.6× |
| UFPT UFP Technologies, Inc. compare | 3.0× |
| Medical Devices industry median | 2.7× |
| Healthcare sector median | 3.1× |
| Market median | 1.6× |
What Current ratio is
Current Ratio shows whether a company’s short-term assets are enough to cover the bills and debts it must pay within the next year.
Current Assets (Total) ÷ Current Liabilities (Total)
More on AXGN
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement